These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Weir MR; Sperling RS; Reicin A; Gertz BJ Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311 [TBL] [Abstract][Full Text] [Related]
6. Endotoxin-induced myocardial tumor necrosis factor-alpha synthesis depresses contractility of isolated rat hearts: evidence for a role of sphingosine and cyclooxygenase-2-derived thromboxane production. Grandel U; Fink L; Blum A; Heep M; Buerke M; Kraemer HJ; Mayer K; Bohle RM; Seeger W; Grimminger F; Sibelius U Circulation; 2000 Nov; 102(22):2758-64. PubMed ID: 11094044 [TBL] [Abstract][Full Text] [Related]
7. Hypercholesterolemia and chronic ischemia alter myocardial responses to selective cyclooxygenase-2 inhibition. Chu LM; Robich MP; Lassaletta A; Burgess T; Liu Y; Sellke N; Sellke FW J Thorac Cardiovasc Surg; 2011 Sep; 142(3):675-81. PubMed ID: 21762932 [TBL] [Abstract][Full Text] [Related]
8. Current perspective on the cardiovascular effects of coxibs. Konstam MA; Weir MR Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293 [TBL] [Abstract][Full Text] [Related]
9. Induction of prostacyclin by steady laminar shear stress suppresses tumor necrosis factor-alpha biosynthesis via heme oxygenase-1 in human endothelial cells. Di Francesco L; Totani L; Dovizio M; Piccoli A; Di Francesco A; Salvatore T; Pandolfi A; Evangelista V; Dercho RA; Seta F; Patrignani P Circ Res; 2009 Feb; 104(4):506-13. PubMed ID: 19122175 [TBL] [Abstract][Full Text] [Related]
10. What have we learned from the large outcomes trials of COX-2 selective inhibitors? The rheumatologist's perspective. Hochberg MC Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S15-22. PubMed ID: 11695246 [TBL] [Abstract][Full Text] [Related]
11. Effects of cyclooxygenase inhibition on canine coronary artery blood flow and thrombosis. Hong TT; Huang J; Barrett TD; Lucchesi BR Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H145-55. PubMed ID: 17921331 [TBL] [Abstract][Full Text] [Related]
12. Dual functionality of cyclooxygenase-2 as a regulator of tumor necrosis factor-mediated G1 shortening and nitric oxide-mediated inhibition of vascular smooth muscle cell proliferation. Haider A; Lee I; Grabarek J; Darzynkiewicz Z; Ferreri NR Circulation; 2003 Aug; 108(8):1015-21. PubMed ID: 12912810 [TBL] [Abstract][Full Text] [Related]
13. Biomedicine. Back to an aspirin a day? Vane JR Science; 2002 Apr; 296(5567):474-5. PubMed ID: 11964462 [No Abstract] [Full Text] [Related]
18. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Niederberger E; Manderscheid C; Grösch S; Schmidt H; Ehnert C; Geisslinger G Biochem Pharmacol; 2004 Jul; 68(2):341-50. PubMed ID: 15194006 [TBL] [Abstract][Full Text] [Related]
19. Effects of nonsteroidal anti-inflammatory drugs on prostacyclin and thromboxane in the kidney. Lomnicka M; Karouni K; Sue M; Wessel LA; Bing RJ Pharmacology; 2003 Jul; 68(3):147-53. PubMed ID: 12784086 [TBL] [Abstract][Full Text] [Related]
20. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Hermann M; Camici G; Fratton A; Hurlimann D; Tanner FC; Hellermann JP; Fiedler M; Thiery J; Neidhart M; Gay RE; Gay S; Lüscher TF; Ruschitzka F Circulation; 2003 Nov; 108(19):2308-11. PubMed ID: 14597594 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]